ADXS (Ayala Pharmaceuticals) Stock Based Compensation: $0.00 Mil (TTM As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADXS Ayala Pharmaceuticals Inc ADXS
12 GF Score
Price $0.60
View Full Analysis

What is Ayala Pharmaceuticals Stock Based Compensation?

Ayala Pharmaceuticals ADXS 12 Stock Based Compensation is $0.00 Mil as of Dec. 2023. GuruFocus rates ADXS with a GF Score™ of 12/100.

Ayala Pharmaceuticals's Stock Based Compensation for the three months ended in Dec. 2023 was $-0.09 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Ayala Pharmaceuticals Stock Based Compensation Related Terms

Ayala Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Ayala Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ayala Pharmaceuticals Stock Based Compensation Chart

Ayala Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial 0.73 1.57 2.68 2.24 1.22

Ayala Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.33 0.00 0.09 -0.09
ADXS
12GF Score
Ayala Pharmaceuticals Inc ADXS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ayala Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Stock Based Compensation of $0.00 Mil mean?
Ayala Pharmaceuticals (ADXS) has a Stock Based Compensation of $0.00 Mil as of Dec. 2023. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ayala Pharmaceuticals and its competitors.
Is Ayala Pharmaceuticals' Stock Based Compensation too high?
Ayala Pharmaceuticals' current Stock Based Compensation is $0.00 Mil. Overall, Ayala Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Ayala Pharmaceuticals' Stock Based Compensation compare to SCPX and PBM?
Ayala Pharmaceuticals' Stock Based Compensation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Ayala Pharmaceuticals and its competitors. Ayala Pharmaceuticals's current Stock Based Compensation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ayala Pharmaceuticals stock overvalued right now?
Ayala Pharmaceuticals (ADXS) has a current Stock Based Compensation of $0.00 Mil. The current Stock Based Compensation is $0.00 Mil. Ayala Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Ayala Pharmaceuticals (ADXS), the current Stock Based Compensation is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ayala Pharmaceuticals Business Description

Address 9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
12GF Score

Get the complete analysis for ADXS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price